title: Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
abstract: BACKGROUND
  Recurrent tumor growth of colorectal carcinoma at the peritoneal site remains an unsolved problem. The aim of this study was to investigate whether the substance taxol (paclitaxel) can alter intraperitoneal tumor spread using different modes of drug application.
  
  
  METHODS
  Intraperitoneal tumor growth was induced using a tumor cell transfer model (10(6) cells) in rats divided into 3 groups: (1) taxol was applied directly into the abdominal cavity, intraperitoneally or intravenously, immediately following intraperitoneal tumor cell transfer; (2) early postoperative intraperitoneal and intravenous chemotherapy was administered on days 5, 10 and 15 after surgical intervention using an intraperitoneal or intravenous port-a-cath; (3) control group. Thirty days after tumor cell transfer, rats were sacrificed, and tumor weight, number of nodes (at greater omentum and peritoneum) and ascites volume were determined.
  
  
  RESULTS
  Taxol generated a significant inhibitory effect on peritoneal tumor growth. Direct intraoperative intraperitoneal application of taxol induced a more pronounced effect compared with early postoperative intraperitoneal application of the antineoplastic drug. Both application modes were superior to the intravenous route (no significant effect).
  
  
  CONCLUSIONS
  Taxol appears to be a potential chemotherapeutic drug providing a significant effect in the therapeutic management of peritoneal carcinomatosis under experimental conditions. Combination of taxol with cytostatic agents and new drugs generating different effector mechanisms may help to further diminish or even to prevent intraperitoneal tumor growth.
authors.affiliation: Department of Surgery, University Hospital, Magdeburg, Germany. arndth@t-online.de
authors.forename: Arndt
authors.initials: A
authors.lastname: Hribaschek
authors.forename: Frank
authors.initials: F
authors.lastname: Meyer
authors.forename: Regine
authors.initials: R
authors.lastname: Schneider-Stock
authors.forename: Matthias
authors.initials: M
authors.lastname: Pross
authors.forename: Karsten
authors.initials: K
authors.lastname: Ridwelski
authors.forename: Hans
authors.initials: H
authors.lastname: Lippert
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000628:therapy; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D051381:Rats; D011912:Rats, Inbred ACI; D011919:Rats, Inbred Strains
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel